The economics of adalimumab for ulcerative colitis

被引：1

作者：

Xie, Feng ^{[1
]}

机构：

[1] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 4A6, Canada

来源：

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | 2015年 / 15卷 / 03期

关键词：

adalimumab; cost-effectiveness; economics; infliximab; ulcerative colitis; MAINTENANCE THERAPY; INDUCTION THERAPY; LOST RESPONSE; OPEN-LABEL; INFLIXIMAB; EFFICACY; INTOLERANCE; MODERATE; METAANALYSIS; REMISSION;

D O I：

10.1586/14737167.2015.1031113

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Ulcerative colitis is a chronic inflammatory disease, characterized by diffuse mucosal inflammation in the colon. Adalimumab, as a TNF- blocker, offers a safe and efficacious treatment option for patients with moderate to severe ulcerative colitis and refractory or intolerant to conventional medications; however, its cost-effectiveness profile has not yet been well established. Future economic evaluations should choose appropriate comparators in the context of target-reimbursement decision making and focus on cost-effectiveness over a long time horizon.

引用

页码：373 / 377

页数：5

共 50 条

[31] Effectiveness of adalimumab in severe ulcerative colitis: A systematic review and a meta-analysis
Azadbakht, Saleh
Seighali, Masomeh
Azadbakht, Salehe
Azadbakht, Morteza
HEALTH SCIENCE REPORTS, 2024, 7 (07)
[32] Costs of dose escalation among ulcerative colitis patients treated with adalimumab in Germany
Poellinger, Bernadette
Schmidt, Wolfgang
Seiffert, Anna
Imhoff, Heidi
Emmert, Martin
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2019, 20 (02): : 195 - 203
[33] Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral Center
Gagnon, Ann-Lorie
Beauchesne, William
Tessier, Laurence
David, Charles
Berbiche, Djamal
Lavoie, Alexandre
Michaud-Herbst, Alban
Tremblay, Karine
CROHNS & COLITIS 360, 2021, 3 (04)
[34] Ulcerative Colitis - from Ultrastructural to Clinical Outcome in Adalimumab Therapy
Fratila, O.
Craciun, C.
Ilias, T.
Tent, L.
PROCEEDINGS OF THE 49TH ANNUAL SCIENTIFIC MEETING OF THE EUROPEAN SOCIETY FOR CLINICAL INVESTIGATION, 2015, : 185 - 190
[35] Adalimumab in patients with ulcerative colitis
Balatsos, V.
Anastasiou, Th.
Karoumpalis, I.
Katselis, I.
Vagia, A.
Skandalis, N.
ANNALS OF GASTROENTEROLOGY, 2010, 23 (01): : 64 - 66
[36] Adalimumab: A 'Maillon Faible' in the Treatment of Ulcerative Colitis?
Roblin, Xavier
Paul, Stephane
JOURNAL OF CROHNS & COLITIS, 2024, 18 (03): : 337 - 338
[37] A critical review of adalimumab for the treatment of moderate-to-severe active ulcerative colitis in children
Pigneur, Benedicte
Ruemmele, Frank M.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (11-12) : 1023 - 1028
[38] A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis
Renna, Sara
Mocciaro, Filippo
Ventimiglia, Marco
Orlando, Rosalba
Macaluso, Fabio Salvatore
Cappello, Maria
Fries, Walter
Mendolaro, Marco
Privitera, Antonino Carlo
Ferracane, Concetta
Pisana, Valentina
Magnano, Antonio
Pluchino, Dario
Inserra, Gaetano
Scarpulla, Giuseppe
Garufi, Serena
Carroccio, Antonio
Siringo, Sebastiano
Di Mitri, Roberto
Cottone, Mario
Orlando, Ambrogio
DIGESTIVE AND LIVER DISEASE, 2018, 50 (12) : 1292 - 1298
[39] Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis
Ananthakrishnan, Ashwin N.
Cagan, Andrew
Cai, Tianxi
Gainer, Vivian S.
Shaw, Stanley Y.
Savova, Guergana
Churchill, Susanne
Karlson, Elizabeth W.
Kohane, Isaac
Liao, Katherine P.
Murphy, Shawn N.
INFLAMMATORY BOWEL DISEASES, 2016, 22 (04) : 880 - 885
[40] Histological Remission in Ulcerative Colitis in Deep Remission under Treatment with Adalimumab
Tursi, Antonio
Nenna, Rosanna
Musci, Giovanni
Elisei, Walter
Picchio, Marcello
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2021, 30 (01) : 55 - 58

← 1 2 3 4 5 →